Dr. Robert Figlin on the Future of Treatment for Patients With RCC
Dr. Robert Figlin talks about how TKI therapies, currently in the second-line setting, could function as first-line treatment or in the adjuvant setting.
Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, talks about how TKI therapies, currently in the second-line setting, could function as first-line treatment or in the adjuvant setting.
Figlin says checkpoint inhibitors and next generation single-agent or combination TKIs may be the future of treatment. He adds that while currently sequences of drugs have prolonged survival for kidney cancer patients, it still means patients are receiving drugs for an elongated period of time. Figlin says that he hopes upcoming novel approaches to treating kidney cancer could mean better treatment for patients with less toxicities.
In a recent study published byThe New England Journal of Medicine, patients with advanced renal cell carcinoma had an improved overall survival rate of 5.4 months while on nivolumab (Opdivo) versus everolimus (Afinitor).
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
